Cardiac software debuts
Amersham Health launched analytical software designed to help practitioners better identify, measure, and manage costs associated with myocardial perfusion imaging studies on Jan. 8. MPOptions models economic factors affecting office-based and outpatient
Amersham Health launched analytical software designed to help practitioners better identify, measure, and manage costs associated with myocardial perfusion imaging studies on Jan. 8. MPOptions models economic factors affecting office-based and outpatient imaging centers and provides what-if scenarios to explore alternatives for delivering nuclear cardiology services efficiently and cost-effectively. The software calculates costs in several categories, including labor, capital equipment, facility, pharmaceutical, and supplies. MPOptions was developed with Amersham funding by physicians at Cardiovascular Consultants in St. Louis and Georgetown University in Washington, DC.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.
